PREX2, SPTA1 and PCLO were present in ≥20% of GC patient tumors in the TP53MUT group; however, only 12.6% PREX2 and 16.8% PCLO mutations, with no available data of SPTA1, in the TP53WT group (in the table of Fig. 2b). This evidence concerns the gene PREX2 and gastric cancer.